AFMD News and Press, Affimed N.V. From 11/05/20

Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets Proof of concept, preclinical assessment to establish activity and feasibility of the comb...

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts highlighting data related to the company’s lead innate...

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2020 results on Tuesday, November 10, 2020 and ...

OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes. Affimed to collaborate with NKMax America for SNK01 natural killer cell therapy. For further details see: OraSure's Emergency Use...

Affimed ([[AFMD]] -2.2%) and NKMax America have entered into a clinical collaboration agreement to investigate the combination of former's AFM24 with later's autologous NK cell product SNK01.The companies plan to explore the combination in a first-in-human proof-of-concept trial in patie...

Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE ® ) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumors Pre-clinical data substantiates synergy between Affimed’s ICE ...

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that preclinical data from its collaboration with The University of Texas MD...

Westwater Resources (WWR) +53%.Xtant Medical Holdings (XTNT) +29% after regaining compliance with NYSE's continued listing standards.Alteryx (AYX) +25% on raising Q3 revenue guidance.CBAK Energy Technology (CBAT) +22%.Ocean Power Technologies (OPTT) +20%.Oxbridge Re Holdin...

Affimed (AFMD) perks 9% premarket after successfully dosing the first patient with allogeneic cord blood-derived natural killer (cbNK) cells preloaded with innate cell engager AFM13 and has moved on to the AFM13 monotherapy phase of the treatment cycle in adult patients wi...

First of its kind clinical study combining a Natural Killer (NK) cell product with an innate cell engager (ICE ® ) Study investigates NK cells preloaded with AFM13, followed by subsequent weekly treatment with AFM13 monotherapy in patients with recurrent or re...